Trial Profile
A trial to study Lumacaftor/Ivacaftor tolerance and outcomes in patients with cystic fibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2016
Price :
$35
*
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- 27 Jun 2016 New trial record
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society